Artiva Biotherapeutics, Inc. to start Phase 3 AlloNK trial in refractory RA after strong early results

Artiva Biotherapeutics, Inc. to start Phase 3 AlloNK trial in refractory RA after strong early results
Artiva to start Phase 3 RA trial

Artiva Biotherapeutics, Inc. has announced positive initial clinical results for its AlloNK cell therapy across multiple autoimmune diseases.

The company also shared that it reached alignment with the U.S. Food and Drug Administration regarding plans to initiate a Phase 3 registrational trial targeting refractory rheumatoid arthritis in 2026. These early findings bolster the therapeutic potential of AlloNK as a treatment option for patients with challenging autoimmune conditions. Further details about the trial timeline and protocol are expected as preparations advance.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.